Publications
Enroll-HD is both a worldwide observational study and a clinical research platform supporting various studies and trials, with an overall objective to accelerate HD therapeutic development. Clinical data and biosamples collected in Enroll-HD and other HD studies are made available through the Enroll-HD platform to any verified researcher per the Clinical Data and Biosample Access Policy to extract as much knowledge as possible. As ever, we are enormously grateful to the thousands of participants and families around the world who selflessly give their time and energy, as well as to the dedicated staff at the clinical sites who make Enroll-HD possible.
When publishing their findings, researchers using these data and biosamples are expected to adhere to the Enroll-HD publication policy, including full acknowledgement of the individuals who contributed to the collection of the Enroll-HD data. The publications hosted here have all used the Enroll-HD datasets that are periodically made available and illustrate some of the areas of HD research that Enroll-HD is directly influencing.
If your publication that uses Enroll-HD data is not included in this gallery, or you know of a publication that should be included, then please let us know at info@chdifoundation.org. In the near future we will also be including publications that use other HD study datasets available through the Enroll-HD platform, please let us know if this applies to a publication of yours.
Title
Journal
Achenbach J, Faissner S, Saft C
Differential diagnosis of Chorea-HIV infection delays diagnosis of Huntington's disease by years
Ghazaleh N, Houghton R, Palermo G, Schobel SA, Wijeratne PA, Long JD
Ranking the predictive power of clinical and biological features associated with disease progression in Huntington's disease
Achenbach J, Saft C
Data from Enroll-HD: Is the prevalence of juvenile and pediatric Huntington's disease overestimated?
Symonds AL, Macerollo A, Foy K, Alusi SH, Davies R
Genetic and environmental contributors to neurodegeneration: An exploration of the effects of alcohol on clinical features of Huntington's disease using the Enroll-HD global platform
Int J Environ Res Public Health
May 12, 2021
18 (10) :5113
18 (10) :5113
PMID: 34065918
Ogilvie AC, Gonzalez-Alegre P, Schultz JL
Diabetes mellitus is associated with an earlier age of onset of Huntington's disease
Hentosh S, Zhu L, Patino J, Furr JW, Rocha NP, Furr Stimming E
Sex differences in Huntington's disease: evaluating the Enroll-HD database
Oosterloo M, de Greef BTA, Bijlsma EK, Durr A, Tabrizi SJ, Estevez-Fraga C, de Die-Smulders CEM, Roos RAC
Disease onset in Huntington's disease: when is the conversion?
Mov Disord Clin Pract
March 31, 2021
8 (3) :352-360
8 (3) :352-360
PMID: 33816663
PMCID: 8015887
DOI: 10.1002/mdc3.13148
Achenbach J, Saft C, Faissner S
Longitudinal evaluation of the effect of tricyclic antidepressants and neuroleptics on the course of Huntington's disease-data from a real world cohort
Schultz JL, Saft C, Nopoulos PC
Association of CAG repeat length in the Huntington gene with cognitive performance in young adults
van der Zwaan KF, Jacobs M, van Zwet EW, Roos RAC, de Bot ST
Predictors of working capacity changes related to Huntington's disease: A longitudinal study
Mühlbäck A, Frank W, Klempířová O, Bezdíček O, Schmitt L, Hofstetter N, Landwehrmeyer GB, Klempíř J
Validation study of a German cognitive battery for Huntington's disease: Relationship between cognitive performance, functional decline, and disease burden
Griffin BA, Booth MS, Busse M, Wild EJ, Setodji C, Warner JH, Sampaio C, Mohan A
Estimating the causal effects of modifiable, non-genetic factors on Huntington disease progression using propensity score weighting
Parkinsonism Relat Disord
January 13, 2021
83 :56-62
83 :56-62
PMID: 33476879
Ranganathan M, Kostyk SK, Allain DC, Race JA, Daley AM
Age of onset and behavioral manifestations in Huntington's disease: An Enroll-HD cohort analysis
Lu AT, Narayan P, Grant MJ, Langfelder P, Wang N, Kwak S, Wilkinson H, Chen RZ, Chen J, Simon Bawden C, Rudiger SR, Ciosi M, Chatzi A, Maxwell A, Hore TA, Aaronson J, Rosinski J, Preiss A, Vogt TF, Coppola G, Monckton D, Snell RG, William Yang X, Horvath S
DNA methylation study of Huntington's disease and motor progression in patients and in animal models
Mills JA, Long JD, Mohan A, Ware JJ, Sampaio C
Cognitive and motor norms for Huntington's disease
Carlozzi NE, Boileau NR, Roberts A, Dayalu P, Hanifan DL, Miner JA, Claassen D, Provost EM
Understanding speech and swallowing difficulties in individuals with Huntington disease: Validation of the HDQLIFE Speech Difficulties and Swallowing Difficulties Item Banks
Schultz JL, Moser AD, Nopoulos PC
The association between CAG repeat length and age of onset of juvenile-onset Huntington's disease
Achenbach J, von Hein SM, Saft C
Functional and cognitive capacity differ in dystonic motor subtypes when compared to choreatic and hypokinetic-rigid motor subtypes in Huntington's disease
Langbehn DR, Hersch S
Clinical outcomes and selection criteria for prodromal Huntington's disease trials
Kwa L, Larson D, Yeh C, Bega D
Influence of age of onset on Huntington's disease phenotype
Tremor Other Hyperkinet Mov
July 9, 2020
10 (21)
10 (21)
PMID: 32775035
PMCID: 7394225
DOI: 10.5334/tohm.536
Jaini A, Yomtoob J, Yeh C, Bega D
Understanding HD psychosis: an analysis from the Enroll-HD database
Tremor Other Hyperkinet Mov
July 7, 2020
10 (16)
10 (16)
PMID: 32775030
PMCID: 7394199
DOI: 10.5334/tohm.395
Yhnell E, Furby H, Lowe RS, Brookes-Howell LC, Drew CJG, Playle R, Watson G, Metzler-Baddeley C, Rosser AE, Busse ME
A randomised feasibility study of computerised cognitive training as a therapeutic intervention for people with Huntington's disease (CogTrainHD)
Witkowski G, Jachinska K, Stepniak I, Ziora-Jakutowicz K, Sienkiewicz-Jarosz H
Alterations in transcranial sonography among Huntington's disease patients with psychiatric symptoms
Gaßner H, Jensen D, Marxreiter F, Kletsch A, Bohlen S, Schubert R, Muratori LM, Eskofier B, Klucken J, Winkler J, Reilmann R, Kohl Z
Gait variability as digital biomarker of disease severity in Huntington's disease
De Lucia N, Peluso S, Roca A, De Michele G, Trojano L, Salvatore E
Perseverative behavior on verbal fluency task in patients with Huntington's disease: a retrospective study on a large patient sample
Harris KL, Kuan WL, Mason SL, Barker RA
Antidopaminergic treatment is associated with reduced chorea and irritability but impaired cognition in Huntington's disease (Enroll-HD)
Julayanont P, Heilman KM, McFarland NR
Early-motor phenotype relates to neuropsychiatric and cognitive disorders in Huntington's disease
Ellis N, Tee A, McAllister B, Massey T, McLauchlan D, Stone T, Correia K, Loupe J, Kim KH, Barker D, Hong EP, Chao MJ, Long JD, Lucente D, Vonsattel JPG, Pinto RM, Elneel KA, Ramos EM, Mysore JS, Gillis T, Wheeler VC, Medway C, Hall L, Kwak S, Sampaio C, Ciosi M, Maxwell A, Chatzi A, Monckton DG, Orth M, Landwehrmeyer GB, Paulsen JS, Shoulson I, Myers RH, van Duijn E, Rickards H,…Holmans P
Genetic risk underlying psychiatric and cognitive symptoms in Huntington's disease
Schultz JL, Harshman LA, Langbehn DR, Nopoulos PC
Hypertension is associated with an earlier age of onset of Huntington's disease
Steventon JJ, Furby H, Ralph J, O’Callaghan P, Rosser AE, Wise RG, Busse M, Murphy K
Altered cerebrovascular response to acute exercise in patients with Huntington's disease
Fazio P, Fitzer-Attas CJ, Mrzljak L, Bronzova J, Nag S, Warner JH, Landwehrmeyer B, Al-Tawil N, Halldin C, Forsberg A, Ware J, Dilda V, Wood A, Sampaio C, Varrone A, PEARL-HD and LONGPDE10 study collaborators
PET molecular imaging of phosphodiesterase 10A: An early biomarker of Huntington's disease progressio
Gunn S, Maltby J, Dale M
Assessing mental health difficulties of persons with Huntington's disease: Does informant presence make a difference?
J Neuropsychiatry Clin Neurosci
February 28, 2020
PMID: 32102601
Goh AMY, You E, Perin S, Lautenschlager NT, Clay FJ, Loi SM, Chong T, Ames D, Chiu E, Ellis KA
Alcohol use, mental health, and functional capacity as predictors of workplace disability in a cohort with manifest Huntington's disease
J Neuropsychiatry Clin Neurosci
February 27, 2020
PMID: 32102602
Steventon JJ, Rosser AE, Hart E, Murphy K
Hypertension, antihypertensive use and the delayed-onset of Huntington's disease
Julayanont P, McFarland NR, Heilman KM
Mild cognitive impairment and dementia in motor manifest Huntington's disease: Classification and prevalence
Ciosi M, Maxwell A, Cumming SA, Hensman Moss DJ, Alshammari AM, Flower MD, Durr A, Leavitt BR, Roos RAC, TRACK-HD team, Enroll-HD team, Holmans P, Jones L, Langbehn DR, Kwak S, Tabrizi SJ, Monckton DG
A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes
Drew CJG, Quinn L, Hamana K, Williams-Thomas R, Marsh L, Dimitropoulou P, Playle R, Griffin BA, Kelson M, Schubert R, Muratori L, Reilmann R, Rosser A, Busse M
Physical activity and exercise outcomes in Huntington disease (PACE-HD): Protocol for a 12-month trial within cohort evaluation of a physical activity intervention in people with Huntington disease
Yomtoob J, Yeh C, Bega D
Ancillary service utilization and impact in Huntington's disease
Li F, Li K, Li C, Luo S, PREDICT-HD and ENROLL-HD Investigators of the Huntington Study Group
Predicting the risk of Huntington's disease with multiple longitudinal biomarkers
J Huntingtons Dis
August 27, 2019
8 (3) :323-332
8 (3) :323-332
PMID: 31256145
PMCID: 6718328
DOI: 10.3233/JHD-190345
GeM-HD Consortium, Lee JM, Correia K, Loupe J, Kim KH, Barker D, Hong EP, Chao MJ, Long JD, Lucente D, Vonsattel JPG, Pinto RM, Abu Elneel K, Ramos EM, Mysore JS, Gillis T, Wheeler VC, MacDonald ME, Gusella JF, McAllister B, Massey T, Medway C, Stone TC, Hall L, Jones L, Holmans P, Kwak S, Ehrhardt AG, Sampaio C, Ciosi M,…Myers RH
CAG repeat not polyglutamine length determines timing of Huntington's disease onset
Designed by LONI